These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
646 related articles for article (PubMed ID: 16512896)
21. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. Palacios J; Benito N; Pizarro A; Suárez A; Espada J; Cano A; Gamallo C Am J Pathol; 1995 Mar; 146(3):605-12. PubMed ID: 7534041 [TBL] [Abstract][Full Text] [Related]
22. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma. Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715 [TBL] [Abstract][Full Text] [Related]
23. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Matsumura T; Makino R; Mitamura K Clin Cancer Res; 2001 Mar; 7(3):594-9. PubMed ID: 11297254 [TBL] [Abstract][Full Text] [Related]
24. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Chang HW; Chow V; Lam KY; Wei WI; Yuen A Cancer; 2002 Jan; 94(2):386-92. PubMed ID: 11900224 [TBL] [Abstract][Full Text] [Related]
26. CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation. González-Martínez S; Kajabova VH; Pérez-Mies B; Carretero-Barrio I; Caniego-Casas T; Sarrió D; Moreno-Bueno G; Gión M; Perez-García J; Cortés J; Smolkova B; Palacios J Virchows Arch; 2024 Aug; 485(2):291-297. PubMed ID: 38713384 [TBL] [Abstract][Full Text] [Related]
27. [Detection of free tumor-related DNA in the serum of breast cancer patients]. Zhang JJ; Ouyang T; Wan WH; Deng GR Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882 [TBL] [Abstract][Full Text] [Related]
28. [Promoter methylation profile in breast cancer]. Roa JC; Anabalón L; Tapia O; Martínez J; Araya JC; Villaseca M; Guzmán P; Roa I Rev Med Chil; 2004 Sep; 132(9):1069-77. PubMed ID: 15543763 [TBL] [Abstract][Full Text] [Related]
29. [Methylation status and protein expression of adenomatous polyposis coli (APC) gene in breast cancer]. Liu Z; Yang L; Cui DX; Liu BL; Zhang XB; Ma WF; Zhang Q Ai Zheng; 2007 Jun; 26(6):586-90. PubMed ID: 17562262 [TBL] [Abstract][Full Text] [Related]
30. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533 [TBL] [Abstract][Full Text] [Related]
31. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789 [TBL] [Abstract][Full Text] [Related]
32. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Cheng CW; Wu PE; Yu JC; Huang CS; Yue CT; Wu CW; Shen CY Oncogene; 2001 Jun; 20(29):3814-23. PubMed ID: 11439345 [TBL] [Abstract][Full Text] [Related]
33. Alterations of the 16q22.1 and 16q24.3 chromosomal loci in sporadic invasive breast carcinomas: correlation with proliferative activity, ploidy and hormonal status of the tumors. Kouvaraki M; Gorgoulis VG; Rassidakis GZ; Liodis P; Koutroumbi E; Markopoulos C; Gogas J; Kittas C Anticancer Res; 2001; 21(2A):991-9. PubMed ID: 11396193 [TBL] [Abstract][Full Text] [Related]
34. DNA methyltransferase 1 expression and promoter methylation of E-cadherin in mucoepidermoid carcinoma. Shieh YS; Shiah SG; Jeng HH; Lee HS; Wu CW; Chang LC Cancer; 2005 Sep; 104(5):1013-21. PubMed ID: 15999364 [TBL] [Abstract][Full Text] [Related]
35. Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis. Azarschab P; Porschen R; Gregor M; Blin N; Holzmann K Genes Chromosomes Cancer; 2002 Oct; 35(2):121-6. PubMed ID: 12203775 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of protein expression and DNA methylation profiles detected by pyrosequencing in invasive breast cancer. Zmetakova I; Danihel L; Smolkova B; Mego M; Kajabova V; Krivulcik T; Rusnak I; Rychly B; Danis D; Repiska V; Blasko P; Karaba M; Benca J; Pechan J; Fridrichova I Neoplasma; 2013; 60(6):635-46. PubMed ID: 23906298 [TBL] [Abstract][Full Text] [Related]
37. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565 [TBL] [Abstract][Full Text] [Related]
38. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512 [TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. Zou D; Yoon HS; Perez D; Weeks RJ; Guilford P; Humar B J Pathol; 2009 Jun; 218(2):265-72. PubMed ID: 19294736 [TBL] [Abstract][Full Text] [Related]
40. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Paredes J; Albergaria A; Oliveira JT; Jerónimo C; Milanezi F; Schmitt FC Clin Cancer Res; 2005 Aug; 11(16):5869-77. PubMed ID: 16115928 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]